FIELD: medicine; pharmaceutics.
SUBSTANCE: object 1 is a pharmaceutical composition of an anti-TRBV9 antibody for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in a T-cell receptor, containing an anti-TRBV9 antibody, a histidine or acetate buffer, water for injections, object 2 is use of a pharmaceutical composition of an anti-TRBV9 antibody for treating a disease or disorder mediated by T-lymphocytes carrying a TRBV9 segment in a T-cell receptor in a subject in need thereof.
EFFECT: stability of pharmaceutical compositions of anti-TRBV9 antibodies, which can be used for treating a disease or disorder mediated by human T-cell receptor carrying TRBV9.
124 cl, 36 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF ANTIBODY-DRUG CONJUGATE AND ITS LYOPHILIZATION | 2018 |
|
RU2789476C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
